Articles

Immunotherapy drug blinatumomab showed benefit in pediatric patients with relapsed acute lymphoblastic leukemia who have minimal residual disease following chemotherapy.

Blinatumomab Versus Chemotherapy in Relapsed B-Acute Lymphoblastic Leukemia

A combination therapy of carfilzomib, dexamethasone, and daratumumab extended progression-free survival when compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 

Combo Therapy Increases Progression-Free Survival in Relapsed, Refractory Multiple Myeloma

An oral formulation of azacitidine improved overall survival in patients with acute myeloid leukemia in first remission.

Oral Form of Azacitidine Improves Overall Survival in Patients with AML in Remission

The current observational, longitudinal study focused on patient-reported outcomes on functioning, symptoms, and quality of life in patients with chronic lymphocytic leukemia.

Venetoclax, Obinutuzumab Combo Leads to Improved Quality of Life in Patients with CLL

A poster presented at the American Society of Hematology Annual Meeting and Exposition assessed disease-related health care utilization and costs among patients with multiple myeloma.
 

Disease-Related Hospital Utilization, Drug Costs Drive Economic Burden in Multiple Myeloma

In a session at the American Society of Hematology Annual Meeting and Exposition, held December 7-10 in Orlando, Florida, experts presented on the evolution of CLL therapy, how to make treatment decisions, and what’s to come in the future based on ongoing studies.
 

Frontline CLL Therapy: Considerations for Selecting Targeted Therapies

Jennifer Woyach, MD, associate professor at The Ohio State University, gives an overview of the new data in chronic lymphocytic leukemia being presented at the 2019 American Society of Hematology Annual Meeting and Exposition. 

ASH 2019: New CLL Data Show Sustained Efficacy with Targeted Combo Therapies

Jennifer Woyach, MD, associate professor at The Ohio State University, discusses current clinical trials going on in the chronic lymphocytic leukemia space that are most likely to impact the treatment landscape.

Ongoing CLL Trials Most Likely to Change Clinical Practice

Videos

Jennifer Woyach, MD, associate professor at The Ohio State University, explains how patient-specific factors can help determine treatment decisions in chronic lymphocytic leukemia. 

Using Patient-Specific Factors to Guide Treatment Decisions in CLL

The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.
 